Epclusa Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

epclusa

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;  ; velpatasvir 100mg;  ;  ;   - tablet - 400mg/100mg - active: sofosbuvir 400mg       velpatasvir 100mg       excipient: copovidone croscarmellose sodium opadry ii pink 85f94644 magnesium stearate microcrystalline cellulose - indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults.

Vosevi Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

vosevi

gilead sciences (nz) - sofosbuvir 400mg;  ;  ;  ; velpatasvir 100mg;  ;  ;  ; voxilaprevir 100mg;   - film coated tablet - active: sofosbuvir 400mg       velpatasvir 100mg       voxilaprevir 100mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f170040 - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults.

Biktarvy Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

biktarvy

gilead sciences (nz) - bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir;  ; emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide;   - film coated tablet - active: bictegravir sodium 52.45mg equivalent to to 50 mg bictegravir   emtricitabine 200mg         tenofovir alafenamide fumarate 28.04mg equivalent to to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry brown 85f165072 - biktarvy is indicated for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25 kg who are antiretroviral therapy (art)-na?ve or to replace the current antiretroviral regimen in those who are virologically-suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen at the start of therapy with no history of treatment failure, and no known substitutions associated with resistance to the individual components of biktarvy.

STRIBILD tenofovir disoproxil fumarate 300mg, emtricitabine 200 mg, elvitegravir 150 mg, cobicistat 150 mg tablet bottle Australien - engelska - Department of Health (Therapeutic Goods Administration)

stribild tenofovir disoproxil fumarate 300mg, emtricitabine 200 mg, elvitegravir 150 mg, cobicistat 150 mg tablet bottle

gilead sciences pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg; emtricitabine, quantity: 200 mg; elvitegravir, quantity: 150 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; lactose monohydrate; microcrystalline cellulose; silicon dioxide; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - stribild is indicated as a single tablet regimen for the treatment of hiv infection in treatment-na?ve adults. stribild is also indicated in certain virologically suppressed (hiv1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of stribild (tenofovir df, emtricitabine or elvitegravir). stribild is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide hiv-1 reverse transcriptase inhibitors.

Vemlidy Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

vemlidy

gilead sciences (nz) - tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg;   - film coated tablet - 25 mg - active: tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 85f120028 purified water - indicated for the treatment of chronic hepatitis b in adults.

Descovy Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

descovy

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide;   - film coated tablet - 200mg/10mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 11.2mg equivalent to 10 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry grey 85f97517 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

Descovy Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

descovy

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide;   - film coated tablet - 200mg/25mg - active: emtricitabine 200mg         tenofovir alafenamide fumarate 28mg equivalent to 25 mg tenofovir alafenamide   excipient: croscarmellose sodium magnesium stearate microcrystalline cellulose opadry blue 85f105057 - descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and adolescents aged 12 years and older with body weight at least 35 kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy. descovy is not for use in pre-exposure prophylaxis (prep)?.

Eviplera Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

eviplera

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: emtricitabine 200mg       rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg   tenofovir disoproxil fumarate 300mg       excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry polysorbate 20 povidone pregelatinised maize starch purified water - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).

Odefsey Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

odefsey

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ;  ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine 25 mg;  ; tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg;   - film coated tablet - 200mg/25mg/25mg - active: emtricitabine 200mg         rilpivirine hydrochloride 27.5mg equivalent to rilpivirine 25 mg   tenofovir alafenamide fumarate 28.04mg equivalent to tenofovir alafenamide 25 mg   excipient: croscarmellose sodium opadry ii grey 85f17636 lactose monohydrate magnesium stearate microcrystalline cellulose polysorbate 20 povidone - indicated as a complete regimen for the treatment of hiv-1 infection in adults and adolescents (12 years and older with a body weight at least 35 kg) with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of odefsey.